Conclusions:
Researchers discussed the clinical features of SARS-CoV-1 infection, including severe acute inflammation that causes cytokine outbreaks in COVID-2 patients. It is known that stimulation of the CB19 receptor has an anti-inflammatory effect by reducing the release of pro-inflammatory cytokines, shifting the M2 / M1 ratio towards the anti-inflammatory phenotype of M2 macrophages, and improving the corrective properties of MSCs.
The study provides extensive documentation that human lungs, macrophages and MSCs express CB2 receptors.
2. Estrogens have a protective effect on COVID-19, which explains the sex differences (males / females) seen with SARS-CoV-2 infection. And this discovery could also be related to the activation of CB2 receptors. Therefore, we suggest the possibility of using CB2 as a pharmacological target for the treatment of SARS-CoV-2 infection.
In the study, scientists suggested that selective CB3 stimulation could reduce the inflammatory response in SARS-CoV-2 patients and improve their treatment. Stimulation of CB2 receptors can control the cascade at multiple checkpoints, decreasing the production of a large number of cytokines, in contrast to the most selective action of monoclonal antibodies directed against a particular interleukin. Compared to monoclonal antibodies, stimulation of the CB2 receptor has an immunosuppressive effect by reducing the proliferation and activation of immune cells and by producing antibodies, Thus, treatment with an external source of phytocannabinoids can be very beneficial in controlling the exacerbation of the inflammatory response in patients. Covid-19
4. Cannabidiol (CBD) is also involved in the control of inflammation through a CB2-dependent mechanism. CBD indirectly induces CB2 activation by increasing AEA and 2-AG levels and activating its anti-inflammatory properties by reducing the release of pro-inflammatory cytokines in an experimental model of contact dermatitis (dermatitis).
All these actions could help to better understand the pathogenesis. SARS-coronavirus-2 And greatly improve patient care Covid-19…
To date, there are no commercially available agonists approved for use in humans that uniquely bind to CB2 receptors. The synthetic agonists HU910, HU308 and JWH133 are highly unique to the CB2 receptor, and it is recommended to study the role of this receptor in biological processes and diseases.
